The antiviral drug was one of the drugs recently used to treat Donald Trump’s viral infection
Gilead Sciences Inc’s remdesivir had little or no effect on the length of hospital stay or the chances of survival of patients with COVID-19, a World Health Organization (WHO) clinical trial has found.
The antiviral drug, among the first to be used as a treatment for COVID-19, was one of the drugs recently used to treat the coronavirus infection of US President Donald Trump.
The results come from the WHO “Solidarity” trial, which evaluated the effects of four potential treatment regimens, including remdesivir, hydroxychloroquine, the anti-HIV drug combination lopinavir / ritonavir and interferon, in 11,266 adult patients in over 30 countries.
The study found that diets appeared to have little or no effect on 28-day mortality or the length of in-hospital treatment in patients hospitalized for COVID-19, the WHO said Thursday.
The results of the test have not yet been reviewed and have been uploaded to the medRxiv preprint server.
Earlier this month, data from a US study on Gilead’s remdesivir showed that treatment reduced recovery time from COVID-19 by five days compared to patients given placebo in a trial of 1,062 patients.
“The emerging data (WHO) appear inconsistent, with stronger evidence from several randomized controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir,” Gilead told Reuters.
“We are concerned that the data from this global, open-label trial has not received the rigorous review required to allow for constructive scientific discussion, especially given the limitations of the trial design.
WHO chief scientist Soumya Swaminathan said on Wednesday that during the study, hydroxychloroquine and lopinavir / ritonavir were stopped in June after being ineffective, but other trials emerged. are being prosecuted in more than 500 hospitals and 30 countries.
“We are looking at the sequel. We are looking at monoclonal antibodies, we are looking at immunomodulators and some of the newer antiviral drugs that have been developed in the last few months,” Swaminathan said.
Remdesivir received emergency use authorization from the United States Food and Drug Administration on May 1, and has since been authorized in several countries.
(Except for the title, this story was not edited by GalacticGaming staff and is posted from a syndicated feed.)
